See the original blog here:
https://www.discoveriesinhealthpolicy.com/2026/06/hhs-oig-releases-legal-viewpoint-on.html
Here is a longer Chat GPT opinion.
##
OIG Advisory Opinion 26-11:
Why the Free MCED Report Survived, and Where the Reasoning Could Fail
OIG Advisory Opinion 26-11 is important less because it “approves free testing” than because it shows how carefully OIG will parse a free molecular diagnostic add-on when the add-on is investigational, clinically plausible, non-billed, and tightly tethered to a separately covered screening test. The opinion should not be read as a general permission slip for laboratories to bundle free molecular information with federally reimbursed testing. OIG expressly found that the arrangement implicated both the Anti-Kickback Statute and the Beneficiary Inducements CMP. The favorable result came only after OIG concluded that the specific facts made the fraud-and-abuse risk sufficiently low.
The arrangement involved a precision oncology company offering a Medicare-covered, FDA-approved blood-based colorectal cancer screening test. Using the same blood sample, the company also ran an algorithmic multi-cancer detection analysis and furnished a free supplemental report to consenting patients. The supplemental report identified positive or negative signals for multiple cancers, including cancers for which there is no broadly recommended screening modality. The multi-cancer detection test was investigational, CLIA-validated, under development for FDA submission, and not separately reimbursed.
The threshold legal problem was straightforward. A free supplemental report is a thing of value. OIG emphasized that the report was valuable in part because the company hoped it would become reimbursable in the future. It could influence a beneficiary to select the company’s colorectal cancer screening test over other CRC screening modalities and thereby select the company’s laboratory. It could also create downstream billable physician visits or referrals. Thus, the arrangement created remuneration under the AKS framework and generated prohibited remuneration under the Beneficiary Inducements CMP. OIG also found that no AKS safe harbor applied. Nor did the preventive-care exception save the arrangement, because neither the CRC blood test nor the multi-cancer detection test was listed in the USPSTF Guide, even though CRC screening itself is broadly recommended.
The opinion therefore turns on enforcement discretion, not formal exemption. Several factual “locks” made the arrangement tolerable.
First, OIG relied heavily on the preexisting, independent clinical order. The supplemental report was available only where the patient already had a valid order for the Medicare-covered CRC screening test from an independent, non-affiliated physician who would use the results in patient management. This reduced the risk that the free report itself was the engine of utilization. The Medicare-paid service was not open-ended; it was a CRC screening test covered no more than once every three years for eligible beneficiaries.
Second, the supplemental analysis used the same specimen. There was no additional blood draw, procedure, or separately reimbursed laboratory service. This mattered because the free item did not create an additional claim to Medicare. OIG accepted that follow-up visits after a positive result might occur, but treated them as clinically grounded in the information returned rather than as utilization inappropriately caused by the free add-on.
Third, the report sat in a clinically meaningful gap. OIG noted that several cancers included in the MCD report lack USPSTF-recommended screening tests. This did not create a preventive-care exception; legally, that exception failed. But it mattered to OIG’s risk assessment because the free report could provide information not otherwise broadly available through recommended screening.
Fourth, the company avoided referral-linked provider economics. Physicians were not compensated for ordering the CRC test or for opting in to receive the supplemental report. The supplemental report was available regardless of the physician’s volume or value of referrals for the CRC test, the MCD test, or other company products. This is a critical guardrail. Had physicians received fees, data-collection payments, consulting opportunities, or other benefits tied to ordering or opting in, the opinion’s logic would likely deteriorate quickly.
Fifth, marketing was constrained. The company did not actively market the supplemental report as a provider benefit, did not conduct targeted or incentivized marketing for the report, and did not engage in direct-to-consumer promotion of the free supplemental report. Educational materials were pre-approved, neutral, and objective, and disclosed performance limitations. OIG also noted social-media controls, including instructions to physicians not to post about the free report and monitoring for third-party promotion. This is not cosmetic. In OIG’s analysis, restrained communication helped distinguish informed clinical availability from a promotional inducement.
Sixth, the competitive posture was unusual. The company’s laboratory was the only laboratory performing the CRC screening test. Therefore, a patient choosing that CRC test would choose that laboratory even without the supplemental report. This reduced, though did not eliminate, steering and unfair-competition concerns. The arrangement would be much harder to defend if many laboratories offered the same covered primary test and one laboratory used a free multi-cancer add-on to divert volume.
The opinion also contains built-in expiration points. The company certified that the arrangement would continue only until the MCD test received FDA approval as a medical device or was covered by Medicare under an NCD. That is sensible: once the MCD test becomes an approved or covered stand-alone product, giving it away for free beside a paid CRC test looks less like investigational information and more like free commercial value used to obtain federal program business.
The most important lesson is that the AO protects a narrow transitional fact pattern. It could fall through if the supplemental report becomes promotional, if the test becomes reimbursable, if the company adds DTC advertising, if physicians receive compensation or other economic benefits, if the analysis requires additional reimbursed services, if eligibility expands beyond independently ordered covered CRC screening, if performance limitations are obscured, or if the arrangement disadvantages competing laboratories in a more ordinary competitive market.
For molecular diagnostics companies, AO 26-11 is not a broad blessing of “free plus paid” diagnostic bundling. It is closer to a map of conditions under which OIG may tolerate a no-charge investigational add-on: no extra Medicare payment, no provider compensation, independent ordering, careful consent and data collection, neutral education, restrained marketing, and a credible clinical rationale. Remove enough of those conditions, and the same arrangement becomes the familiar fraud-and-abuse problem OIG says it continues to worry about: free items or services used to influence federally reimbursed ordering.
##
Key source anchors: OIG states the opinion is requester-specific and fact-bound, and loses force if material facts are omitted, misrepresented, or change. It expressly finds AKS and Beneficiary Inducements CMP remuneration, no safe harbor, and no preventive-care exception. The favorable result rests on the same-sample/no-extra-cost structure, independent physician order, no physician compensation, limited neutral materials, lack of DTC promotion, and reduced steering concerns because only the requester’s lab performs the CRC test. The formal limitations section also confirms that no other party or arrangement may rely on the opinion, and that OIG gives no opinion on Stark, FCA, or other law.
